Health Condition 1: M170- Bilateral primary osteoarthritis of knee
Conditions
Interventions
Intervention1: Bone Marrow Aspirate Concentrate: Group A: Single dose of 5 ml subchondral BMAC (both tibial and femoral medial condyles) on day 0
Group B: Single dose of 5 ml intraarticular BMAC injec
Sponsors
Ashwini R
Eligibility
Inclusion criteria
Inclusion criteria: Patients with age between 40 to 60 years of both sex Patients OA knee with Grade II and III. Primary OA knee patients not responding to analgesics Patients who are willing to take part in the study after informed consent
Exclusion criteria
Exclusion criteria: Post traumatic knee Stiffness History of Infective joint disease Patients with a history of previous surgeries on the knee Comorbid or Pathology of ipsilateral Hip or foot joint pathology Patients with rheumatoid arthritis, inflammatory arthritis or polyarticular arthritis, and autoimmune diseases Any other defect of the ipsilateral limb like Shortening Patients with history of prior corticosteroid injection at treatment site within 3 months of duration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the pain relief of BMAC versus BMA injections in primary osteoarthritis knee with VAS score at different follow-up time points. Timepoint: Day 0 At the end of 1,3,6,12,24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the functional outcome of BMAC versus BMA injections in primary osteoarthritis knee with WOMAC and KOOSTimepoint: Day 0 At the end of 1,3,6,12,24 months ;To compare the cartilage thickness and the healing of subchondral bone lesions of BMAC and BMA in primary osteoarthritis knee via MOCARTTimepoint: Day 0 At the end of 24 months | — |
Countries
India
Contacts
Public ContactAshwini R
Faculty of medicine- Sri Lalithambigai Medical College and Hospital
Outcome results
None listed